Loading stock data…
Amgen Inc. (AMGN)
$432.42-4.57 (-1.05%)
Market ClosedLast close Aug 28
Amgen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amgen Inc. in the Healthcare sector is trading at $432.42 with a market capitalization of $238.1B. Wall Street consensus targets $388.48 (29 analysts), implying a -10.2% move over the next 12 months. The stock is currently near its 52-week high of $447.03, remaining 23.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -10.2% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.62B↓ | $9.87B↑ | $9.56B↑ | $9.18B↑ | $8.15B |
| Gross Profit | $5.87B↓ | $6.89B↑ | $6.47B↑ | $6.17B↑ | $5.18B |
| Operating Income | $2.67B↓ | $2.72B↑ | $2.53B↓ | $2.66B↑ | $1.18B |
| Net Income | $1.82B↑ | $1.33B↓ | $3.22B↑ | $1.43B↓ | $1.73B |
Peer Comparison
JNJUNHPFE
Fundamentals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$238.06B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
27.47
Beta
Defensive asset. Lower volatility than the S&P 500.
0.41
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.30%
ROE
Elite ROE. Management converts capital into profit efficiently.
74.80%
Volume
Today's trading volume
1.73M
Recent News
AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?
Amgen and AstraZeneca (LSE:AZN) reported positive top line Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with clinically meaningful improvements through week 52. That kind of readout often prompts investors to revisit AstraZeneca stock. Even with a steady stream of late stage trial updates around TEZSPIRE, Tagrisso combinations and Enhertu, AstraZeneca’s share price has drifted, with a year to date share price return down 10.87% at £121.14. The 5 year total shareholder return of...
Amgen Stock Signals Its Confidence. The Market Agrees.
The real bet is on what lies beyond this year's performance: a pipeline that could change everything.
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?
Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success
Tezspire met both primary endpoints in an esophagitis trial, but AstraZeneca shares slipped roughly 0.6% Thursday.
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
AstraZeneca's Tezspire delivers positive CROSSING data in EoE, meeting all primary and secondary endpoints and supporting its expansion potential.